Pfizer Inc. (NYSE: PFE) and Other Biotechnology Service Companies Could Reach a Market Capitalization of $151.10 Billion

Pfizer Inc. (NYSE: PFE) is among the companies in the biotechnology services market that analysts expect to grow in 2022. These companies could amass a market cap of $151.10 billion in 2022. Other significant players in this category include Precision for Medicine, BioAlps, Novo Nordisk, Pfizer, Fisher BioService, and Novartis.

The FDA and CDC are yet to decide on children’s vaccine

Meanwhile, parents with children aged six months to 4 years are waiting for the Food and Drug Administration (FDA) and the Center for Disease Control and Prevention (CDC) to decide on the Pfizer and BioNTech SE (NASDAQ: BNTX) vaccine.

The FDA has asked Pfizer to submit results for two doses after the company admitted they were not effective in children. The regulator has started that available information doesn’t support the option for three doses.

This vaccine comes when the vaccination rates for eligible children are low. For example, only 55% of children between 12 and 17 have received a shot, while 20% of those between 5-11 have received vaccinations.

Pfizer ends partnership with Ionis Pharmaceuticals Inc (NASDAQ: IONS)

Pfizer and Ionis Pharmaceuticals Inc (NASDAQ: IONS) are also ending their partnership on vupanorsen. The companies were developing the drug to treat severe hypertriglyceridemia and reduce the risk of cardiovascular disease.

Although the researchers observed a significant decrease in non-density lipoprotein, the results didn’t support the program’s continuation. Moreover, they found that using the drug caused an increase in liver fat. Taking a higher dose also increases the enzyme, aspartate aminotransferase, and alanine aminotransferase.

Pfizer has originally bought rights for vupanorsen from Ionis in 2018. However, these results have prompted the company to hand them back.

False Social Media posts on Japan claiming that the government is imposing a state of emergency due to the effects of the Pfizer vaccine have been on the rise. The posts claim that Japan is suing Pfizer for genocide and asking it for compensation while doctors ask people not to get the vaccine.

While the country has imposed a quasi-state of emergency, this is not due to the vaccine but instead because of the effects of COVID-19 on the population. The restoration includes encouraging people to work from home and stopping them from eating out in large groups.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.